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erties of “classic” tumor suppressor genes. First, theyCharles J. Sherr
Howard Hughes Medical Institute are recessive and undergo biallellic inactivation in tu-
mors. Second, inheritance of a single mutant allele ac-Department of Genetics and Tumor Cell Biology
St. Jude Children’s Research Hospital celerates tumor susceptibility, because only one addi-
tional mutation is required for complete loss of gene332 North Lauderdale
Memphis, Tennessee 38105 function. Hence, a germline mutation can be the underly-
ing cause of a familial cancer syndrome that exhibits an
autosomally dominant pattern of inheritance. Third, the
same gene is frequently inactivated in sporadic cancers.
Beyond this, strict constructionists might argue that a
tumor suppressor is a gene that, when restored to activ-Molecular genetic studies of familial cancer syn-
dromes identified and defined the recessive nature of ity, can reverse the tumorigenic properties of a cell, a
requirement that rarely has been met experimentally.tumor suppressor genes and resolved the paradox
of why tumors arising in such families exhibited an Indeed, given that tumor suppressors can prevent the
acquisition of additional deleterious mutations that mightautosomally dominant pattern of inheritance. Subse-
quent characterization of tumor suppressor proteins otherwise provide cancer cells with a further selective
advantage, tumor suppressor gene inactivation mightrevealed their widespread involvement in sporadic
cancers and pinpointed key mechanisms that protect well allow further genetic changes that could confer
resistance to their restoration at a later time.animals against tumor development. We now recog-
nize that tumor suppressor genes regulate diverse cel- Because many others have reviewed the properties
of individual tumor suppressor genes in detail, I focuslular activities, including cell cycle checkpoint re-
sponses, detection and repair of DNA damage, protein here on selected members in order to exemplify the
scope of their biologic activities. I then touch briefly onubiquitination and degradation, mitogenic signaling,
cell specification, differentiation and migration, and the concepts of haploinsufficiency (“one-hit” inactiva-
tion) and combinatorial interactions between genes thattumor angiogenesis. Their study has become a center-
piece of contemporary cancer research. more subtly provide tumor resistance. Due to limitations
of space, I have chosen to emphasize the roles of repre-
sentative tumor suppressor genes in human cancer,It has long been recognized that cancers arise as a result
making less frequent references to mouse model systems.of somatic mutations, a concept dramatically reinforced
by the demonstration that cellular “protooncogenes,”
when mutationally deregulated or abnormally overex- The Checkered History of p53
pressed, contribute to tumor formation (Stehelin et al., The path to discovery of the p53 tumor suppressor—the
1976). Our understanding that many such genes encode starting point for this review (Finlay et al., 1989)—was
proteins that govern processes of cell proliferation, dif- filled with more than a few twists and turns. Linzer and
ferentiation, and development, and that mutations af- Levine (1979) and Lane and Crawford (1979) first de-
fecting their functions constitutively deregulate particu- tected p53 in complexes with SV40 T antigen. Oren and
lar signaling pathways provided us with some of the Levine (1983) cloned p53 cDNA from SV40-transformed
clearest mechanistic insights about how and why cancer cells and reported, as did Robert Weinberg’s laboratory,
cells misbehave (Bishop and Varmus, 1985). The discov- that p53 could collaborate with mutant Ras to transform
ery of genetically dominant, “activated” oncogenes also primary rat embryo fibroblasts (Eliyahu et al., 1984; Par-
fueled the idea that a distinct class of “antioncogenes” ada et al., 1984). On this basis, it was reasonably con-
might oppose their effects and block tumor develop- cluded in the parlance of the time that p53 was an “im-
ment. Indeed, experiments involving somatic cell fusion mortalizing oncogene,” a protein that, like Myc or
and chromosome segregation had pointed to the exis- adenovirus E1A, could collaborate with Ras to transform
tence of genes that could suppress tumorigenicity (Har- primary rodent cells.
ris et al., 1969; Stanbridge, 1976). Over the last 15 years, As a harbinger of what was to come, others found that
many such tumor suppressor genes have been identified the cellular p53 gene was rearranged and inactivated in
(Table 1). Because their cancer-preventive effects usu- mouse erythroleukemia cells by insertion of the Friend
ally require the presence of only a single functional gene, murine leukemia virus into the locus (Mowat et al., 1985).
prototypic tumor suppressor genes are recessive, re- These changes were observed to occur in vivo during
quiring “two-hit” inactivation of both alleles (Knudson, the natural course of virus-induced disease, although
1971, 1973; Comings, 1973). Thus, the earliest attempts the precise nature of the selective advantage conferred
to identify them relied on genetic approaches that fin- by p53 disruption remained unclear. Things began to
gered instances of biallelic gene inactivation, typically further unravel when a murine p53 cDNA derived from
in a setting in which one mutated allele was inherited F9 embryonal carcinoma cells failed to collaborate with
through the germ line and the other was lost somatically. Ras in the cotransformation assay but formed foci of
In retrospect, these features define three cardinal prop- transformed cells when mutated (Hinds et al., 1987).
Ensuing investigations “call(ed) into question what the
correct p53 wild-type sequence is and whether a wild-Correspondence: sherr@stjude.org
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Table 1. Representative Tumor Suppressor Genes
Gene Function Familial Cancer Association Other Major Tumor Types
p53 Transcription factor Li-Fraumeni syndrome 50% of cancers
RB Transcriptional corepression Retinoblastoma Many
INK4a (p16) Cdk inhibitor (RB activation) Melanoma Many
ARF Mdm2 antagonist (p53 Melanoma Many
activation)
APC Wnt/Wingless signaling Familial adenomatous Colorectal cancer
polyposis
PTCH Hedgehog signaling (receptor) Basal cell nevus (Gorlin) Medulloblastoma, basal cell carcinoma,
syndrome rhabdomyosarcoma
SMAD4/DPC4 TGF- signaling (Transcription Juvenile polyposis Pancreatic and colon cancer
factor) (hamartomas)
PTEN Lipid phosphatase Cowden syndrome Glioblastoma, endometrial, thyroid, and
(phosphoinositide prostate cancers
metabolism)
TSC1,2 GTPase activating protein Tuberous sclerosis Renal cell carcinoma (rare),
complex (mTOR inhibition) (hamartomas) angiofibromas
NF1 GTPase activating protein for Neurofibromatosis Sarcomas, gliomas
Ras
WT1 Transcription factor Wilm’s tumor
MSH2 and MLH1 DNA mismatch repair Hereditary nonpolyposis Endometrial, gastric, ovarian, bladder
colorectal cancer cancer
(Lynch syndrome)
ATM DNA damage sensor (protein Ataxia telangiectasia Lymphoreticular malignancies
kinase) (T-cell lymphoma)
NBS1 DNA repair, S phase checkpoint Nijmegen breakage Lymphoreticular malignancies
control syndrome (T cell
lymphoma)
CHK2 Protein kinase (G1 checkpoint Li-Fraumeni syndrome
control)
BRCA1, BRCA2 DNA repair Familial breast and ovarian
cancer
FA genes DNA repair, S phase checkpoint Fanconi Anemia Acute myelogenous leukemia
VHL E3 ligase recognition factor for Von Hippel-Lindau Renal cell carcinoma, cerebellar
HIF syndrome hemangiosarcoma
type p53 gene can transform cells in culture” (Finlay et and even oncogene activation (Prives, 1998) (Figure 1).
In turn, p53 orchestrates a global transcriptional re-al., 1988). Moreover, the formation of oligomeric com-
sponse that either counters cell proliferation or, moreplexes between the wild-type and mutant p53 proteins
dramatically, induces apoptosis. Its reputation as a tu-raised the possibility that the mutationally inactivated
mor suppressor is secure, as p53 is now recognized toforms might act in a transdominant manner to inhibit the
be the singly most frequently inactivated gene in humanfunction of the wild-type protein (as they can!) (Eliyahu et
cancers (Olivier et al., 2002).al., 1988; Hinds et al., 1989). Finlay and coworkers (1989)
concluded this chapter with their landmark paper dem-
onstrating that p53 can act as a suppressor of transfor- RB, the First “Classic” Tumor Suppressor
mation. Backing up a bit, the cardinal features of tumor suppres-
Recognizing that p53 was deleted in human colorectal sion were first exemplified in studies of retinoblastoma
cancers, analysis of the second p53 allele in tumor cells and Wilm’s tumor before p53 was identified. Alfred
showed that it had sustained mutations, implicating p53 Knudson’s perspective as a pediatrician and cancer ge-
loss as a driving force (Baker et al., 1990). Mutations of neticist sparked his interests in childhood malignancies
p53 were soon documented in many other forms of in which hereditary features were manifest. He articu-
sporadic cancer and were revealed to be a causative lated the idea that retinoblastoma might be caused by
genetic factor in patients with the familial Li-Fraumeni two mutations, one of which might be inherited through
cancer susceptibility syndrome (Malkin et al., 1990). In- the germ line (Knudson, 1971, 1973). Families transmit-
triguingly, the demonstration that p53 is a sequence- ting such mutations would manifest a pattern of domi-
specific DNA binding protein was made only later (Kern nant inheritance, so that affected children would de-
et al., 1991). The wild-type protein was soon revealed velop disease early in life that frequently affected both
to be induced by DNA damage and to cause G1 phase eyes. In nonhereditary cases requiring two de novo mu-
arrest, suggesting that p53 performs a cell cycle “check- tations, the disease would be rare, develop later, and
point” function that guards cells against genotoxic insult be unilateral almost without exception. In 1976, several
(Kastan et al., 1991). We now appreciate that p53 is a groups, Knudson’s among them, used banding tech-
homotetrameric transcription factor that is activated in niques to demonstrate interstitial deletions of chromo-
response to many forms of cellular stress, including some 13q14 in retinoblastoma, leading to speculation
that “the RB gene” might reside at this locus (Knudsonirradiation, hypoxia, drug-induced genotoxic damage,
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metabolism and replication and whose expression is
required to enable cells to enter the DNA synthetic (S)
phase of the cell cycle (Nevins, 2001; Trimarchi and
Lees, 2002). When bound at E2F-responsive promoters,
RB family proteins help to repress gene expression by
recruiting histone deacetylases and chromatin-remod-
eling factors to these loci (Harbour and Dean, 2000).
By contrast, phosphorylation of RB family proteins by
mitogen-activated, cyclin-dependent kinases cancels
RB-mediated repression. Importantly, this provides a
signaling pathway linking extracellular cues to the mo-
lecular apparatus that controls the initiation of DNA repli-
cation in mammalian cells (Weinberg, 1995) (Figure 1).
Loss of RB weakens these controls, dissociating the
cell cycle machinery from extracellular signals, dampen-
ing the ability of proliferating cells to exit the division
cycle, and compromising the execution of RB-depen-
dent differentiation programs in certain tissues.
INK4a-ARF: Regulating RB and p53
Figure 1. RB and p53 Regulate Cell Cycle Checkpoint Controls Given the roles of RB and p53 in tumor suppression, it
Mitogenic signals activate cyclin D-dependent kinases, which phos- would be expected that other gene products that act
phorylate RB and RB family proteins (p107 and p130) to facilitate epistatically to regulate their expression or functions
entry into S phase (top). The Cdk2 inhibitor, p27Kip1, expressed at might also be frequent targets of deregulation in cancer
high levels in quiescent cells, is phosphorylated by cyclin E-Cdk2
cells. Prominent among these is the INK4 family of Cdkin late G1 phase and degraded as cells enter S phase. Constitutive
inhibitors, which block the ability of the cyclin D-depen-oncogenic signals can activate the INK4a/ARF locus. By antagoniz-
ing the activity of cyclin D-dependent kinases, p16INK4a activates RB dent kinases, Cdk4 and Cdk6, to phosphorylate and
and prevents entry into S phase. Mdm2 is a p53-inducible gene that thereby inactivate RB’s growth suppressive functions.
normally acts to terminate the p53 response. The p14ARF protein The founding member, p16INK4a (Serrano et al., 1993) is
inhibits Mdm2 to induce p53, leading either to p53-dependent apo- inactivated in cases of familial melanoma (Kamb et al.,
ptosis or to induction of the Cdk2 inhibitor p21Cip1, inhibition of cyclin
1994) and has since been found to be disabled in manyE/Cdk2, and RB-dependent cell cycle arrest. As cells exit the division
tumor types (Ruas and Peters, 1998). Intriguingly, thecycle, p27Kip1 is stabilized and reaccumulates. DNA damage signals
activate p53 via ARF-independent pathways. INK4a locus encodes a second, structurally and func-
tionally unrelated protein that is also a potent tumor
suppressor. Two alternative transcripts, initiated at sep-
arate promoters and incorporating sequences from dis-et al., 1976; Francke and Kung, 1976; Noel et al., 1976).
Patients with familial tumors who carried constitutional tinct first exons (designated 1 and 1), are each spliced
to common downstream exon sequences that are trans-chromosome 13q14 deletions were observed to have a
50% reduction of esterase D activity in their normal cells lated in alternative reading frames. Whereas the tran-
script that contains exon-1 sequences specifies p16INK4a,but no remaining activity in their tumor cells, indicating
that esterase D and RB were closely linked. One such the mRNA incorporating exon-1 sequences encodes
the alternative reading frame (ARF) protein, designatedpatient had no detectable deletion of chromosome
13q14 in her normal cells but had a missing chromosome p14ARF in humans and p19Arf in the mouse (Quelle et al.,
1995). Equally surprising, the ARF protein activates p5313 in her tumor (Benedict et al., 1983). Hence, surrogate
marker analysis had detected a submicroscopic first by binding directly to the p53 negative regulator Mdm2
and protecting p53 from Mdm2-mediated degradationhit, and subsequent loss of chromosome 13 had likely
inactivated the second RB allele. Using restriction frag- (Sharpless and DePinho, 1999; Sherr, 2001) (Figure 1).
Thus, one locus encodes two proteins, p16INK4a andment length polymorphisms, Cavenee et al. (1983) local-
ized the affected region much more precisely and, im- p14ARF, that functionally interface with RB and p53, re-
spectively. Despite their intimate linkage, the two genesportantly, were able to formally conclude that inherited
and sporadic cases of retinoblastoma lost the same are independently regulated, targeted differentially by
various signals, and separately silenced and mutated incritical allelic sequences. Using probes from the region,
the RB gene was soon cloned (Friend et al., 1986). various forms of cancer. We still do not understand what
purported selective advantage might have led to theirWe now recognize that RB is part of a gene family
that includes two other members, p107 and p130, which economy of gene organization during evolution, particu-
larly since deletions involving INK4a-ARF simultane-collectively corepress genes that regulate programs
governing cell cycle progression, apoptosis, and differ- ously compromise the functions of both RB and p53.
The INK4a-ARF promoters respond to sustained hy-entiation. Like p53, the RB family proteins exert much
of their growth suppressive control during the G1 phase perproliferative signals. As a singular example, constitu-
tive and simultaneous activation of multiple signalingof the cell division cycle. RB family proteins physically
interact with transcription factors, the best character- pathways by oncogenic Ras induces both Ink4a and
Arf, thereby activating both Rb and p53 and arrestingized of which are the E2Fs. These play key roles in
coordinately regulating many genes required for DNA cell proliferation (Serrano et al., 1997). In contrast, the
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loss of Ink4a-Arf extends the replicative capacity of cells the various components undergo phosphorylation by
glycogen synthase kinase-3 (GSK-3). Phosphorylatedin culture, contributes to their establishment as continu-
-catenin is recognized by an E3 ubiquitin protein ligaseously proliferating cell lines, and sensitizes them to
that marks it for degradation by the proteasome (Figuretransformation by oncogenic Ras (Serrano et al., 1996;
2A, left). Wnt signaling inhibits the enzymatic activity ofKamijo et al., 1997). In short, RB, p53, p16INK4a, and p14ARF
GSK-3, stabilizes-catenin, and enables it to associateform part of a signaling network that monitors mitogenic
with TCF/LEF protein complexes to activate the tran-signaling and restrains aberrant growth-promoting sig-
scription of target genes, including those like c-Myc andnals from driving cell cycle progression inappropriately
cyclin D1 (CCND1) that promote proliferation (Figure 2A,(Figure 1). Inactivation of this signaling network occurs
right) (Polakis, 1997; Fearnhead et al., 2001). Disruptionin most, if not all, forms of human cancer.
of the mouse Tcf7/2 gene, whose product forms tran-
scriptionally active complexes with -catenin, depletesLigand-Dependent Signaling
intestinal epithelial stem cells, highlighting the role ofand Tumor Suppression
this signaling pathway in normal intestinal developmentA series of genes known to affect positional identity,
(Korinek et al., 1998).tissue patterning, and proliferation during embryonic de-
Mutations that disable APC terminate the polypeptidevelopment are also targets of mutations in cancer cells.
chain prematurely, canceling its ability to negatively reg-Included in this group are genes such as APC, PTCH,
ulate -catenin turnover and constitutively activatingSMAD4/DPC4, PTEN, TSC1,2, NF1, and WT1 (Table 1).
this signaling pathway (Morin et al., 1997; Korinek et al.,Many such proteins mediate the flow of information from
1997). Mutant forms of -catenin that are resistant toligand-dependent cell surface receptors to families of
phosphorylation and proteasomal turnover have alsonuclear transcription factors that govern both develop-
been detected in colorectal cancers (Morin et al., 1997).mental and proliferative programs. Misregulation of
Apart from its role in transcriptional control, -cateninthese genes might affect a cell’s progression toward a
associates independently with E-cadherin and aids interminally differentiated, nonproliferating state, thereby
cell adhesion. E-cadherin loss has also been observedallowing additional mutations to accumulate until a fully
in epithelial tumors, and its ability to suppress cell trans-tumorigenic phenotype emerges.
formation may similarly result from limiting the amount ofCell specification within certain tissues is a continu-
-catenin available for transcriptional signaling (Gottardious process that occurs throughout the life of an organ-
et al., 2001). Indeed, experimental perturbations thatism. For example, the processes governing the steady
prevent -catenin from entering the nucleus limit theformation of blood cells and the rapid renewal of epithe-
proliferation of colon cancer cells (Shih et al., 2000).lial cells in the intestine and skin rely on functions of
Hedgehog (Hh) proteins (Figure 2B) also play impor-tissue stem cells that can either self-renew or differenti-
tant roles in patterning decisions, acting from early em-ate (Weissman, 2000). Although it has been argued that
bryogenesis onward to specify the body plan and organbetween four and seven mutations must occur to trans-
development. In mammals, three Hedgehog ligandsform a normal cell into a tumor cell (Hanahan and Wein-
[Sonic (S), Desert (D), and Indian (I)] are differentially
berg, 2000), the proliferation and terminal differentiation
expressed in various tissues, although Shh is the best
of renewing cell populations in blood, intestine, skin,
characterized and most ubiquitous. Genetic studies of
and other organs, occur on a temporal scale that may
Hh signaling in Drosophila first pinpointed the key sig-
be too rapid to accommodate the multiple mutations naling components (Murone et al., 1999; Taipale and
required for tumorigenesis. Hence, others have specu- Beachy, 2001), but their exact biochemical functions
lated that cancers arise from mutations in longer resi- remain unclear, and mammalian homologs of each of
dent, tissue stem cell populations, thereby shifting the the Drosophila proteins have not been identified. The
balance between self-renewal and differentiation and key upstream target of the signaling pathway in flies is
misspecifying cell fates and numbers within a target the Ci transcription factor, for which three GLI paralogs
organ (Taipale and Beachy, 2001; Reya et al., 2001). have been identified in mammals. In the absence of Hh
Mutations inactivating the APC gene are responsible signaling, Ci/GLI is thought to repress transcription of
for familial adenomatous polyposis (FAP), a disease in target genes, whereas ligand stimulation reverses this
which hundreds of adenomatous polyps arise in the process (Figure 2B). The Hh receptor, Patched, is an
colon and rectum of affected individuals, and where upstream negative regulator of the signaling pathway.
colorectal cancer invariably follows relatively early in the The PTCH gene was identified as a tumor suppressor in
lives of untreated patients. The responsible gene was Gorlin’s syndrome (Gorlin, 1987), where its inactivation is
assigned to chromosome 5q21 and identified by posi- associated with development of basal cell carcinoma
tional cloning (Groden et al., 1991; Kinzler et al., 1991). (BCC) and medulloblastoma (Johnson et al., 1996; Hahn
Although germline mutations in APC account for the et al., 1996a). As for FAP, in which the loss of APC
early appearance of colorectal tumors in FAP patients, predisposes to the appearance of multiple adenoma-
somatic mutations affecting both APC alleles also occur tous polyps, persons inheriting a dysfunctional PTCH
as early events in80% of sporadic, nonhereditary colo- allele develop numerous BCCs. PTCH mutations have
rectal cancers as well (Powell et al., 1992). also been identified in a significant percentage of pa-
The APC protein interacts with -catenin (Rubinfeld tients with sporadic BCC and medulloblastoma. Again,
et al., 1993; Su et al., 1993), a key component of the the appearance of many differentiated precursor lesions
Wnt/Wingless signaling pathway (Figure 2A). In the ab- in BCC is consistent with the idea that tissue stem cells
sence of a Wnt signal, -catenin associates with a pro- may be targeted.
TGF- signaling (Figure 2C) regulates the expressiontein scaffold complex containing APC and axin, in which
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Figure 2. Tumor Suppressor Proteins Regulating Ligand-Mediated Signaling Pathways
The tumor suppressor proteins APC, PTCH, Smad4/DPC4, PTEN, TSC1,2, and p53 depicted in different images are highlighted by gray shading.
(A) Wnt signaling. In the absence of Wnt ligand (left image), -catenin binds to a destruction complex containing APC, Axin, and GSK-3.
Phosphorylation of-catenin facilitates its recognition by a unbiquitin-conjugating E3 ligase (SCFTRCP) that targets it for proteasomal degradation.
When Wnt binds to its receptor (right image), signaling via Frizzled and Disheveled prevents -catenin phosphorylation and destruction. Import
of -catenin and its binding to TCF/LEF transcription factors induces expression of Wnt target genes (adapted from Polakis, 1997; Fearnhead
et al., 2001). Inactivation of APC mimics the effects of the Wnt signal.
(B) Hedgehog signaling. Most of the molecules involved in transmitting the hedgehog (Hh) signal have been genetically identified in Drosophila,
and some as yet have no counterparts in mammalian cells. In the absence of Hh (left image), the Patched receptor (PTCH) negatively regulates
Smoothened (Smo). The Ci transcription factor in flies (homologous to three GLI genes in mammals) is tethered by the kinesin-like molecule,
Costal-2, to a microtubule-anchored cytoplasmic complex. Following its phosphorylation by protein kinase A (PKA), Ci is recognized by a
Slimb-containing ubiquitin E3 ligase and degraded. It is inferred that Gli is subject to similar control. A fragment of Ci is imported into the
nucleus where it binds to DNA to repress target genes. Binding of Hh to Patched relieves suppression of Smo, disrupts the cytoplasmic
complex, and stabilizes Ci/GLI. Hh signaling also antagonizes a suppressor of the Fused kinase (SuFu), leading to phosphorylation (P) of
different components and facilitating Ci/GLI activation (adapted from Murone et al., 1999). Loss of PTCH constitutively activates the pathway.
(C) TGF- signaling. Binding of TGF- to type I (RI) and type II (RII) receptors triggers phosphorylation (P) of RII and its serine-threonine
protein kinase activity. Receptor (R)-Smads 2 and 3 are phosphorylated and relieved from negative regulation by SARA. The R-Smads bind
Smad4 to form a complex that is imported into the nucleus and mediates expression of TGF--responsive genes. Specificity is dictated by
other DNA binding factors (BF) and by either coactivators or corepressors (CO) that determine the nature of the transcriptional response
(adapted from Siegel and Massague´, 2003). Disruption of SMAD4/DPC4 renders cells resistant to inhibition by TGF-.
(D) Phosphoinositide 3-kinase (PI3K) signaling. PI3K, which is activated via many growth factor receptors, catalyzes the conversion of
phosphatidylinositol (4,5) bis-phosphate [PI(4,5)P2] to PI (3,4,5)P3. The activity of PI3K is opposed by the PTEN lipid phosphatase. PI(3,4,5)P3
recruits the AKT (PKB) kinase to the plasma membrane where it undergoes phosphorylation by PDK1 (not shown) and activation. AKT
phosphorylates substrates that foster cell cycle progression, cancel apoptosis, and facilitate translation of capped mRNAs. The tuberous
sclerosis complex [TSC1 (hamartin) and TSC2 (tuberin)] antagonizes the function of a G protein (Rheb, not shown) whose activity is required
for activity of the mTOR kinase and its ability to promote translation (adapted from Sulis and Parsons, 2003; Tee et al., 2003). Loss of PTEN
upregulates signaling.
of hundreds of target genes that can coordinately re- apoptosis. The direct phosphorylation of Smad proteins
by ligand-activated TGF- receptors facilitates the as-strain epithelial cell proliferation (Siegel and Massague´,
2003). This endows TGF- with the ability to govern sembly of heterooligomeric Smad transcription factor
complexes that bind, together with other specificity fac-complex biological effects, including tissue morphogen-
esis, angiogenesis, cell migration and adhesion, and tors, to the promoters of TGF--responsive genes. This
Cell
240
can result in downregulation of certain genes, such as mismatch repair gene defect will develop cancer, dis-
ease penetrance is high with a lifetime risk of aboutc-Myc, that are required for cell proliferation, as well as
80%. Errors in DNA replication involve either single basethe induction of others, such as those encoding Cdk
mispairing or unfaithful copying of microsatellite DNAinhibitors, that slow cell cycle progression (Shi and Mas-
sequences composed of mononucleotide or dinucleo-sague´, 2003). Smad-4, a component of the active tran-
tide repeats. If the latter errors are uncorrected, micro-scription complex, was first identified in the guise of a
satellite instability ensues. The mismatch repair systemtumor suppressor gene deleted in pancreatic cancer
includes MutS (MSH2, MSH3, MSH6) and MutL (MLH1,(DPC4) (Hahn et al., 1996b). Mutations in SMAD4/DPC4
MLH3, PMS1, PMS2) genes involved in mismatch recog-were subsequently identified in colon cancers (Schutte
nition and repair, respectively. The MSH2 protein as-et al., 1996), and germline mutations are associated with
sembles with either MSH6 or MSH3 to recognize singlefamilial juvenile polyposis (Howe et al., 1998). In turn,
or larger loops of mismatched DNA, respectively, whichmutations affecting the TGF- Type II receptor have also
are then excised by the MLH1/PMS1 complex (Figurebeen detected in colon cancers (Grady et al., 1999).
3A). Most cases (95%) of HNPCC arise from mutationsHence, desensitizing epithelial cells in the pancreas and
in MLH1 and MSH2 (common to both pathways) (Chungcolon to the growth inhibitory properties of TGF-
and Rustgi, 2003). Approximately 15% of sporadic colo-strongly contributes to carcinogenesis.
rectal tumors also exhibit microsatellite instability mostMany receptor systems activate the serine/threonine-
commonly due to epigenetic inactivation of MLH1. Im-specific Akt protein kinase (protein kinase B) whose
portantly, disruption of the mismatch repair systemactivity enhances protein synthesis, cell growth (mass),
leads to a “mutator” phenotype in which resulting ge-cell cycle progression, and survival (Figure 2D). Akt acti-
netic instability ultimately targets other oncogenes andvation depends upon phosphoinositides produced by
tumor suppressor genes to induce tumor formationPI 3-kinase (Cantley, 2002), a process negatively regu-
(Lengauer et al., 1998; Loeb et al., 2003).lated by the lipid phosphatase, PTEN (Maehama and
Like many epithelial tumors, most colon cancers,Dixon, 1999; Sulis and Parsons, 2003). PTEN is ubiqui-
whether of familial or sporadic origin, exhibit a hightously expressed in eukaryotes, and its inactivation in
degree of aneuploidy resulting from inappropriate seg-somatic cells results in constitutively elevated levels of
regation of chromosomes during mitosis. Normal cellsPI(3,4,5)P3. Complete loss of Pten in flies and mice leads
do not progress through mitosis until chromosomes areto early embryonic lethality, and the ability of hypomor-
appropriately aligned on the mitotic spindle, but thephic Akt alleles to rescue the lethality of Pten null Dro-
“spindle checkpoint” that monitors the fidelity of thissophila embryos emphasizes the importance of Akt as
process is frequently disrupted in those colon cancersan effector of this pathway (Stocker et al., 2002). Germ-
that exhibit chromosomal, as opposed to microsatellite,line mutations of PTEN cause four rare human diseases
instability (Cahill et al., 1998). Other mitotic miscues orwith similar clinical features (Sulis and Parsons, 2003),
defective cytokinesis can also lead to ploidy changes.one of which (Cowden syndrome) is associated with
In the presence of functional p53, such cells arrest inmalignant tumor development. Homozygotic inactiva-
G1 phase, but in its absence, they enter S phase andtion of PTEN occurs frequently in glioblastoma multi-
soon become aneuploid after subsequent divisionsforme, endometrial, and advanced prostate cancers.
(Lanni and Jacks, 1998; Nigg, 2002). Aneuploidy in ad-Given the pleiotropic effects of this signaling pathway
vanced cancers can also result from telomere dysfunc-in influencing cell growth (size) and proliferation, as well
tion, which leads to end-to-end chromosome fusionsas in countering the effects of other proapoptotic tumor
and fusion-bridge-breakage cycles that induce p53-suppressors, such as p53 (Figure 2D), it is not surprising
dependent apoptosis (Artandi et al., 2000). Again, p53that PTEN inactivation is a frequent event in many forms
loss enables such cells to survive, resulting in the out-of human cancer.
growth of tumors that exhibit many unbalanced translo-
Cumulatively, these four examples reveal the diversity
cations. Although genes that regulate mitotic progres-
of biochemical mechanisms that can be used to derail
sion, cytokinesis, or telomerase activity in somatic cells
cell growth control signaling pathways. They also illus- can protect against tumor progression, they have not
trate how the developmental history of particular cell as yet been implicated in familial cancer syndromes and
types determines the identity of the pathways that are are not listed in Table 1.
disrupted in different tumor types. Individuals carrying mutations in a number of other
DNA damage response genes are also highly tumor
The DNA Damage Response prone. Genes regulating such processes that have been
and Genome Instability identified in inherited disorders predisposing to various
Persons carrying germline mutations affecting gene forms of cancer include ATM, NBS1, BRCA1, BRCA2,
products that sense or repair DNA damage are particu- CHK2, and the Fanconi anemia (FA) complex (Figure 3B).
larly prone to cancer. Hereditary nonpolyposis colo- The ATM kinase, whose loss of function results in
rectal cancer (HNPCC or Lynch syndrome) represents ataxia telangiectasia, acts as a sensor of DNA damage,
a family of disorders stemming from mutations in genes being activated specifically in response to double-
required for DNA mismatch repair (Ionov et al., 1993; stranded DNA breaks (Figure 3B). Patients with defec-
Fishel et al., 1993). HNPCC accounts for 1%–3% of all tive ATM function are exquisitely sensitive to ionizing
cases of colorectal cancer, in which patients inheriting radiation, although they show no such sensitivity to cer-
a germline mutation develop colon cancers associated tain other DNA damage signals such as UV irradiation,
with loss of the remaining wild-type allele (Chung and which is sensed by the ATM-related kinase ATR. ATM
belongs to an evolutionarily conserved family of proteinsRustgi, 2003). Although not all individuals inheriting a
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Figure 3. Tumor Suppressors Involved in the DNA Damage Response
(A) MSH complexes recognize replication errors resulting in single nucleotide (left) or di/trinucleotide (right) mismatched pairing and recruit
MLH complexes that excise mispaired nucleotides, leading to repair (adapted from Chung and Rustgi, 2003).
(B) Double-strand DNA breaks activate the ATM and ATR kinases, which phosphorylate numerous substrates involved in both checkpoint
control and DNA repair. Phosphorylation of p53 and Mdm2 induce G1 phase arrest. NBS1 phosphorylation inhibits late origin firing and
prevents progression through S phase. Phosphorylation of Cdc25C inhibits the activity of cyclin B/Cdk1 to prevent entry into mitosis.
Phosphorylation of NBS1 and BRCA1 trigger their recruitment to DNA damage foci to facilitate homologous and nonhomologous modes of
DNA repair. Activation of BRCA1 also induces p53 (not shown) (adapted from Kastan and Lim, 2000).
(C) DNA crosslinks activate the Fanconi anemia complex (consisting of the Fanc A, C, E, F, and G proteins) which ubiquitylate Fanc D2, enable
its interaction with BRCA2 (equivalent to Fanc D1), and facilitate repair via homologous recombination (adapted from D’Andrea and Grompe,
2003). As indicated, NBS1 enters into complexes with MRE11 and RAD50, whereas BRCA1 binds to BRCA2, which interacts with the RecA
homolog RAD 51.
that also includes the DNA-dependent protein kinase in homologous recombination and nonhomologous end
joining, respectively, two distinct processes used to re-DNA-PKCS; each of these plays distinct roles in re-
sponses to DNA damage. Following DNA double-strand pair DNA breaks (Figure 3B). Inherited BRCA1 and
BRCA2 mutations are associated with familial breastbreakage, ATM phosphorylates a number of proteins
(including p53, CHK2 kinase, NBS1, BRCA1, and and ovarian cancers, requiring somatic loss of function
of the second allele for tumors to arise. Familial syn-FANCD2) to initiate both cell cycle checkpoint re-
sponses and DNA repair processes (Figure 3B). Activa- dromes account for 5%–10% of all breast cancer cases
and are typified by early adult onset and a predispositiontion of virtually all of the ATM kinase in a cell can be
induced by very few double-strand DNA breaks, im- to multicentric and bilateral disease. Although most fa-
milial breast cancers are due to mutations of one of theplying either that ATM is upregulated in response to
global damage-induced changes in chromosome struc- two BRCA genes, such tumors can also arise in Li-
Fraumeni patients and in those with inherited PTEN defi-ture or through some other amplifying mechanism (Bak-
kenist and Kastan, 2003). In turn, activation of the ATM ciency (see above). The exact biochemical functions of
the BRCA proteins remain unclear, although a physicalsubstrates p53, CHK2, and NBS1 inhibits cell prolifera-
tion, presumably allowing cells an opportunity to repair association of BRCA1 with BRCA2 and the binding of
the latter to RAD51 (a bacterial RecA homolog) at chro-damaged DNA. Indeed, CHK2, like p53, is inactivated
in some Li-Fraumeni families (Bell et al., 1999), whereas mosomal foci of DNA damage strongly implicate the
complex in repairing double-strand breaks by homolo-NBS1 is mutated in the Nijmegen breakage syndrome, a
disease that closely mimics ataxia telangiectasia (Shiloh gous recombination (Scully and Livingston, 2000; Jasin,
2002). Whether BRCA genes are also required for nonho-and Kastan, 2001). Although ATR controls a broader
spectrum of DNA damage responses than does ATM, mologous end joining remains controversial.
Strikingly, mutations of BRCA genes have not beenboth ATR and CHK1 are essential genes and, hence,
not tumor suppressors. observed in sporadic breast or ovarian cancers. If BRCA
loss confers only a weak selective advantage to certainHomozygous mutations in ATM and NBS1 predispose
to lymphomas relatively early in life (Shiloh and Kastan, cell types so that hereditary tumors arise in middle age
or later, there may be little opportunity for sporadic ho-2001). Their involvement most likely reflects the require-
ment for gene rearrangements during early lymphoid mozygous inactivation. Because biallelic BRCA1 loss
activates cell cycle checkpoints that trigger proliferativedevelopment, in which repair errors increase the fre-
quency of chromosomal translocations that are the hall- arrest or apoptosis (Scully and Livingston, 2000), any
tumors that emerge are likely to have acquired mutationsmarks of T and B cell malignancies. ATM is somatically
inactivated in nonfamilial lymphoreticular malignancies, in genes that regulate these processes. Possibly, there
may be a restricted temporal and developmental win-including T cell prolymphocytic leukemia, B-cell chronic
lymphocytic leukemia, and mantle cell lymphoma, fur- dow, during adolescence for example, when epithelial
cells in the breast or ovary that sustain such mutationsther highlighting its role in protecting developing lym-
phocytes from aberrant genomic rearrangements. might not be eliminated (Elledge and Amon, 2002).
Whereas overexpression of cyclin D1 and Her2/Neu,The BRCA genes (in a complex with RAD51) and NBS1
(in a complex with MRE11 and RAD50) play key functions which occurs frequently in sporadic breast cancers, is
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rarely seen in BRCA1-inactivated tumors, p53 mutations
are much more common (Rosen et al., 2003). Such find-
ings suggest a different molecular etiology for the gener-
ation of BRCA1 null and sporadic breast tumors, likely
reflecting the efficacy by which cell cycle checkpoint
controls counteract preexisting genomic instability.
Fanconi anemia complementation groups define eight
different genes, one of which (FANCD1) appears to be
identical to BRCA2 (D’Andrea and Grompe, 2003). This
implicates FA proteins in the process of homologous
recombination, consistent with observations that FA pa-
tients exhibit defective repair of interstrand DNA cross-
links (Figure 3C). FA patients are predisposed to many
types of cancer with acute myelogenous leukemia being
the most common malignancy. Interestingly, ATM-medi-
ated phosphorylation of one of the Fanconi anemia pro-
teins (FANCD2) also plays a role in attenuating DNA
replication by preventing late origin firing (the S phase
checkpoint). Such findings further emphasize the inti-
mate interplay between cell cycle checkpoint control
and DNA repair during the DNA damage response.
Protein Ubiquitination, Turnover, and Suppression
of Tumor Angiogenesis
Tumor growth and metastasis depend upon angiogen-
esis, a process by which quiescent vasculature is in- Figure 4. VHL Regulates HIF Activity to Govern Responses to
Hypoxiaduced to sprout new capillaries. Avascular tumors can-
not expand in size because of a lack of blood supply Under normoxic conditions (top) HIF- subunits are hydroxylated on
both prolyl and asparaginyl residues. Prolyl hydroxylation facilitatesand oxygen, but their ability to switch on the production
HIF- recognition by the VHL-containing E3 ligase containing Cul2,of angiogenic factors explains how they can trigger neo-
and elongins B and C, whereas asparaginyl hydroxylation preventsvascularization, maintain oxygen-dependent ATP pro-
binding of p300/CBP coactivators. During hypoxia, unhydroxylated
duction, expand, and metastasize (Hanahan and Folk- HIF- subunits are stabilized, bind to HIF-, assemble with coactiva-
man, 1996). tors, and activate transcription (adapted from Kaelin, 2002).
Activation of hypoxia-inducible transcription factor
complexes (HIFs) in response to oxygen deprivation
drives the expression of many genes important for an- Key features exemplified by studies of VHL are that
most, if not all, of the systems that prevent tumor devel-giogenesis, red cell production, and glycolysis. These
include key vascular and hematopoietic growth factors, opment are exquisitely sensitive to levels of protein
expression, and that much of the relevant circuitry issuch as vascular endothelial growth factor (VEGF),
erythropoietin, platelet-derived growth factor (PDGF), controlled by ubiquitin-mediated proteolysis. Many path-
ways governing protein degradation are subverted inand TGF (Semenza, 1999). HIF subunits are transcribed
constitutively. However, HIF- proteins undergo prolyl cancer cells. For example, the rates of turnover of
-catenin and Ci/Gli transcription factors (Figure 2) arehydroxylation under normoxic conditions, targeting them
for ubiquitination by the von Hippel-Lindau (VHL) pro- crucial in establishing the thresholds of Shh and Wnt
required for productive signaling. The p53 negative reg-tein-containing E3 ligase and for subsequent de-
struction by the proteasome (Kaelin, 2002). Within this ulator Mdm2 is an E3 ubiquitin ligase that is negatively
regulated by Arf binding and ATM phosphorylation. Dis-multiprotein complex, the VHL protein provides the rec-
ognition motif for prolyl hydroxylated HIF- (Figure 4). ruption of these signaling pathways can be affected by
mutation of motifs (“degrons”) necesssary for degrada-Under hypoxic conditions, unhydroxylated HIF- sub-
units are not recognized by VHL and are therefore stabi- tion (e.g., VHL, -catenin) or by altered expression of
E3 ubiquitin ligases (e.g., Mdm2 amplification). The factlized, enabling them to form transcriptionally active
complexes with HIF- subunits to drive transcription that changes in protein turnover can either promote or
interfere with a signaling pathway suggests that otherof hypoxia-induced promoters. Loss of VHL function
results in constitutive HIF stabilization and predisposes recently discovered components that regulate ubiquiti-
nation will eventually be revealed to act as oncogenesto particular tumors, such as renal clear cell carcinomas,
cerebellar hemangioblastomas, retinal angiomata, and or tumor suppressors.
pheochromocytomas, all of which have a major vascular
component. Tumor formation in the hereditary setting The Basis of Tissue Specificity?
Despite our increasing understanding of the cellular(VHL syndrome) stems from a loss of heterozygosity at
the VHL locus with retention of the mutant VHL allele. functions of many tumor suppressor proteins, we do
not know why the loss of a particular gene contributesSomatic VHL mutations, deletions, and gene silencing
can also be observed in sporadic renal cell carcinomas to tumors in some tissues but not others. Understanding
the involvement of these proteins in specific biochemi-and cerebellar hemangiosarcomas.
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cal pathways provides some insights. For example, Wnt faster in Kip1 null animals, these data argue that a re-
and Shh signaling are central to developmental pro- duced dosage of p27Kip1, rather than its absolute ab-
grams that affect the formation of the intestine and cere- sence, can contribute to cancer susceptibility. The latter
bellum (Korinek et al., 1998; Taipale and Beachy, 2001; concept has been reinforced in investigations of human
Wechsler-Reya and Scott, 2003), and disruption of these cancers, in which hemizygous loss of Kip1 and/or re-
pathways predisposes to colorectal cancers and medul- duced levels of protein expression confer a poor prog-
loblastoma, respectively. But things are not so tidy. Al- nosis (Blain et al., 2003). There is some evidence that
though inactivation of p16INK4a or RB, which function in other Cdk inhibitors, including p21Cip1, p57Kip2, and p18Ink4c
the same biochemical pathway, is observed in many might function in this manner, so this might prove to be
different tumor types, the fact that small cell lung can- a general property of this class of proteins.
cers preferentially acquire RB mutations while lung ade- Several other examples of haploinsufficiency for tu-
nocarcinomas sustain INK4a loss points to a far greater mor suppression have been demonstrated (Cook and
degree of cell type specificity that defies explanation. McCaw, 2000). For example, mice hemizygous for p53
In the case of the DNA damage response, genes such can develop tumors that retain and express wild-type
as ATM and NBS1 specifically detect double-strand p53 protein (Venkatachalam et al., 1998). In the absence
breaks, and their contribution to lymphoid malignancies of a functional Ink4a allele, animals lacking a single Arf
logically reflects a need for fidelity of repair during the allele are strikingly more prone to melanoma develop-
processes of gene rearrangement that generate the im- ment (Krimpenfort et al., 2001). Pten haploinsufficiency
mune repertoire. But, why then does loss of BRCA1 or in mice accelerates tumor progression, and loss of one
BRCA2, which seem to play central roles in checkpoint PTEN allele with preservation of the second is also com-
and repair responses to DNA damage, specifically pre- mon in human tumors, although its role in these settings
dispose to breast and ovarian cancers? It may prove remains controversial (Sulis and Parsons, 2003). A re-
that a functional redundancy of key signaling pathways cent study of mice engineered to express a mutant se-
can protect many tissues from dire consequences of ries of Pten alleles with incrementally decreasing activity
tumor suppressor gene inactivation, whereas particular and penetrance argues strongly that Pten is haploinsuffi-
cell types that lack such compensatory mechanisms are
cient for tumor suppression in prostate cancer (Trotman
at greater risk to undergo transformation. An improved
et al., 2003). In short, bona fide tumor suppressors such
understanding of tumor suppressor functions, particu-
as p53, Arf, and PTEN may well manifest haploinsuffi-
larly as they relate to processes of tissue-specific ex-
cient effects, particularly when combined with collabo-pression, cell differentiation, and tissue development
rating mutations affecting additional oncogenes or tu-will require much more investigation.
mor suppressors.
Haploinsufficiency—When Only One Hit Is Enough
Because of their recessive nature, the traditional ap- Tumor Susceptibility and Resistance
proach to identifying tumor suppressor genes has been The vast majority of human cancers show no obvious
to pinpoint small chromosomal regions of loss-of-heter-
familial inheritance, and it has been suggested that mul-
ozygosity (LOH) that occur in particular tumor types
tiple, low penetrance genes segregating in the human
(and frequently in familial cancers), to narrow the critical
population confer cancer susceptibility and resistance
region by deletion mapping, and finally to search the
to environmental carcinogens (Balmain et al., 2003; Loebintact homologous chromosomal segment for mutated
et al., 2003). These low penetrance genes might onlygenes whose functions can be demonstrated to protect
act combinatorially in a dosage-dependent manner toagainst cancer development. However, this strategy will
determine cancer predisposition, incrementally affect-fail under circumstances in which the second allele is
ing processes such as carcinogen metabolism, DNAepigenetically silenced or when the targeted gene is
repair efficiency, inflammation, and the immune re-haploinsufficient for tumor suppression, a situation in
sponse to provide relative degrees of tumor resistance.which functional loss of only one allele confers a selec-
Finding this class of genes presents a great challenge.tive advantage for tumor growth (Cook and McCaw,
In principle, a set of polymorphisms used to define hap-2000; Quon and Berns, 2001). Only a few haploinsuffi-
lotypes in genes of potential interest can be associatedcient tumor suppressors have been identified so far,
with cancer development, but this approach requiresbut this may not reflect their actual number—just the
that the appropriate interacting loci are suspected anddifficulties in finding them. Indeed, the ease of pin-
tested. Mouse models of cancer susceptibility providepointing prototypic tumor suppressors within regions of
a way to pinpoint such genes by enriching for combina-LOH seems to have diminished over time, pointing to
tions of alleles that control a specific disease phenotype,the possibility that a larger haploinsufficient class exists
something that is not feasible in humans. Interbreedingbut still eludes detection (Quon and Berns, 2001; Bal-
cancer-resistant and -sensitive mouse strains can pro-main et al., 2003).
vide information about the number and chromosomalOne well-defined instance of haploinsufficiency in the
location of genes involved in susceptibility to variousmouse involves the Cdk inhibitor, p27Kip1 (Fero et al.,
forms of cancer (Balmain and Nagase, 1998). Such map-1998). Animals lacking one copy of Kip1 develop tumors
ping is time consuming and labor intensive, but rapidspontaneously late in life and are highly sensitive to
advances in the human and mouse genome projectstumor induction by chemical carcinogens; however, the
have helped to accelerate progress in detecting modi-tumors that arise retain the normal Kip1 allele, which
encodes a fully functional protein. Although tumors arise fier loci.
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